Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kamira Maharaj

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Blood Advances|January 4, 2018
Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemiaKamira Maharaj, Eva Sahakian, Javier Pinilla-Ibarz
Frontiers in Immunology|August 18, 2022
Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapiesKamira Maharaj, Angimar Uriepero, Eva Sahakian, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|May 22, 2025
Correction to: Evaluation of a pilot cancer patient navigation program in the limited‑resource setting of Trinidad and TobagoKimberly Badal, Nalisha Monroe, Alisha Mohamed, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|November 15, 2024
Correction: Evaluation of a pilot cancer patient navigation program in the limited-resource setting of Trinidad and TobagoKimberly Badal, Nalisha Monroe, Alisha Mohamed, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|September 24, 2024
A Cancer Patient Navigation Training Program for Limited-Resource Settings: Results from 5 Years of TrainingKimberly Badal, Nalisha Monroe, Alisha Mohamed, et al.
Frontiers in Immunology|December 17, 2020
HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 ModelKamira Maharaj, John J Powers, Melanie Mediavilla-Varela, et al.
Blood Advances|November 15, 2018
Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemiaKamira Maharaj, John J Powers, Alex Achille, et al.
Blood Advances|July 8, 2020
The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cellsKamira Maharaj, John J Powers, Alex Achille, et al.
Blood Advances|February 12, 2025
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent modelWael Gamal, Nienke B Goedhart, Helga Simon-Molas, et al.
Gynecologic Oncology|April 30, 2023
Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinomaKatelyn F Handley, Sumit Mehta, Alexandra L Martin, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Blood Advances|January 4, 2018
Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemiaKamira Maharaj, Eva Sahakian, Javier Pinilla-Ibarz
Frontiers in Immunology|August 18, 2022
Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapiesKamira Maharaj, Angimar Uriepero, Eva Sahakian, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|May 22, 2025
Correction to: Evaluation of a pilot cancer patient navigation program in the limited‑resource setting of Trinidad and TobagoKimberly Badal, Nalisha Monroe, Alisha Mohamed, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|November 15, 2024
Correction: Evaluation of a pilot cancer patient navigation program in the limited-resource setting of Trinidad and TobagoKimberly Badal, Nalisha Monroe, Alisha Mohamed, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|September 24, 2024
A Cancer Patient Navigation Training Program for Limited-Resource Settings: Results from 5 Years of TrainingKimberly Badal, Nalisha Monroe, Alisha Mohamed, et al.
Frontiers in Immunology|December 17, 2020
HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 ModelKamira Maharaj, John J Powers, Melanie Mediavilla-Varela, et al.
Blood Advances|November 15, 2018
Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemiaKamira Maharaj, John J Powers, Alex Achille, et al.
Blood Advances|July 8, 2020
The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cellsKamira Maharaj, John J Powers, Alex Achille, et al.
Blood Advances|February 12, 2025
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent modelWael Gamal, Nienke B Goedhart, Helga Simon-Molas, et al.
Gynecologic Oncology|April 30, 2023
Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinomaKatelyn F Handley, Sumit Mehta, Alexandra L Martin, et al.
Pageof 2